Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)

NACompletedINTERVENTIONAL
Enrollment

315

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

May 13, 2020

Study Completion Date

April 29, 2021

Conditions
Alzheimer DiseaseAmyloid Beta-PeptidesRisk AssessmentEducationNeuropsychological TestsNeuroimaging
Interventions
BEHAVIORAL

Alzheimer's Disease Risk Disclosure

Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.

BEHAVIORAL

Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure

"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."

Trial Locations (4)

19104

University of Pennsylvania, Philadelphia

27705

Duke University, Durham

48109

University of Michigan, Ann Arbor

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

collaborator

University of Michigan

OTHER

collaborator

Duke University

OTHER

collaborator

Boston University

OTHER

collaborator

National Institute on Aging (NIA)

NIH

lead

Brigham and Women's Hospital

OTHER